




# PHARMACEUTICAL 2021

Theriva Biologics Inc.  
Rank 301 of 402





# PHARMACEUTICAL 2021

Theriva Biologics Inc.  
Rank 301 of 402

The relative strengths and weaknesses of Theriva Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theriva Biologics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Theriva Biologics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is -19%, being 66% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	7,934
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,966
Liabilities, Non-Current	186
Other Assets	302
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	44
Other Revenues	0
Property and Equipment	174
Research and Development	5,131
Selling, General and Administrative Expense	5,029

Output Variable	Value in 1000 USD
Assets	8,410
Liabilities	3,152
Expenses	10,160
Revenues	0
Stockholders Equity	5,258
Net Income	-10,116
Comprehensive Net Income	-10,116
Economic Capital Ratio	-19%